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Abstract We investigate here the effects of the incorporation of
the nucleoside analogs araC (1-L-D-arabinofuranosylcytosine)
and ganciclovir (9-[(1,3-dihydroxy-2-propoxy)methyl] guanine)
into the DNA binding recognition sequence for the GATA-1
erythroid transcription factor. A 10-fold decrease in binding
affinity was observed for the ganciclovir-substituted DNA
complex in comparison to an unmodified DNA of the same
sequence composition. AraC substitution did not result in any
changes in binding affinity. 1H-15N HSQC and NOESY NMR
experiments revealed a number of chemical shift changes in both
DNA and protein in the ganciclovir-modified DNA-protein
complex when compared to the unmodified DNA-protein
complex. These changes in chemical shift and binding affinity
suggest a change in the binding mode of the complex when
ganciclovir is incorporated into the GATA DNA binding site.
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1. Introduction
Nucleoside analogs have found widespread use in modern
medicine but relatively little information is available concern-
ing the molecular mechanisms that account for their potency.
Many of these analogs are incorporated into DNA but do not
act as direct chain terminators, suggesting a structural origin
for their inhibitory e¡ects. Despite the lack of information
about these structural e¡ects, very few studies have been
aimed at determining the e¡ects of these analogs on protein-
DNA interactions. In the present study, we look at two clin-
ically relevant nucleoside analogs and their e¡ects on a DNA
binding protein when incorporated into DNA oligonucleo-
tides.
The nucleoside analog 9-[(1,3-dihydroxy-2-propoxy)-
methyl]guanine (ganciclovir, DHPG) is an e¡ective antiviral
agent used in the treatment of a variety of herpes simplex
virus (HSV) and cytomegalovirus (CMV) infections. Ganci-
clovir has been used most frequently to treat patients with
immune system de¢ciencies such as AIDS patients and those
undergoing chemotherapy and bone marrow transplants [1^6].
Recently, ganciclovir has found additional use in the form of
a gene therapy agent in the treatment of malignant tumors
[7^15].
Although ganciclovir has found many clinical uses, a com-
plete understanding of its mechanism of action is not avail-
able. Ganciclovir is a simple analog of deoxyguanosine that
lacks the 2P carbon atom of normal deoxyguanosine but still
retains a 3P and 5P hydroxyl group, allowing it to be incorpo-
rated into internal positions in DNA. Ganciclovir is converted
to the chiral (S)-triphosphate form in virally infected cells
where it may competitively inhibit DNA polymerases. The
analog can also become incorporated into newly synthesized
DNA where it interferes with further DNA replication. The
level of ganciclovir incorporation into DNA has been corre-
lated with its toxic e¡ects on treated cells [16,17]. DNA po-
lymerases incorporate ganciclovir into primer strands fol-
lowed by an additional nucleotide before chain extension is
strongly inhibited [18,19].
We have recently determined the solution structure of a
DNA duplex containing ganciclovir at an internal position
of the sequence [20]. Signi¢cant structural distortions localized
around the ganciclovir site were observed, including a kink in
the sugar-phosphate backbone at the site of ganciclovir incor-
poration. Other structural abnormalities included changes in
the conformation of the residue immediately 3P to the ganci-
clovir residue. This deoxyribose ring exhibited a C2P endo
conformation in an unmodi¢ed control DNA of the same
sequence but assumed an A-type C3P endo conformation in
the modi¢ed DNA. In addition to the unusual sugar confor-
mation, an A-type glycosidic torsion angle was also observed
at this residue.
The nucleoside analog arabinosylcytosine (1-L-D-arabino-
furanosylcytosine, araC) is structurally equivalent to deoxycy-
tosine but possesses a hydroxyl group at the 2P position of the
deoxyribose ring in an arabinose orientation. It is used clin-
ically to treat various forms of leukemia [21,22]. AraC is con-
verted to araCTP and may competitively inhibit DNA polym-
erases. This analog is also incorporated into DNA primer
strands and inhibits chain extension [23^28]. The solution
structure of a DNA duplex containing araC has recently
been described [29]. Although no major distortions were ob-
served in the structure when compared to a control sequence,
31P relaxation studies indicated a decrease in conformational
mobility around the araC site [30].
While several laboratories, including ours, have examined
the structural e¡ects of these and other nucleoside analogs in
free duplex DNA, it cannot be assumed that the structural
changes observed in the free DNA predominate in a DNA-
protein complex. Although numerous studies have been car-
ried out on the biochemical e¡ects of araC and ganciclovir on
DNA polymerase function, structural studies on polymerase-
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DNA complexes have proven to be quite challenging. In ad-
dition, it is unlikely that the consequences of incorporation of
these analogs into DNA are limited to DNA polymerases. For
example, it has recently been shown that incorporation of the
nucleoside analog 1(2-deoxy-2-£uoro-L-D-arabinofuranosyl)-
5-iodouracil (FIAU) into DNA had signi¢cant e¡ects on the
binding of the transcription factors AP-1 and TFIID to their
target DNA sequences [31]. Thus, the biological activity and/
or cytotoxicity of nucleoside analogs may be due, in part, to
the ability of these compounds to alter DNA-protein contacts
and thereby modulate gene expression.
We have chosen to examine the e¡ects of nucleoside ana-
logs in the context of a model DNA binding protein ^ the
DNA binding domain of the chicken erythroid transcription
factor GATA-1 (cGATA-1). The GATA-1 transcription fac-
tor is required for transcription in erythroid cell lines and has
been shown to be required for normal hematopoietic develop-
ment [32^34]. Interestingly, ganciclovir has been shown to
inhibit normal hematopoiesis [35,36]. GATA-1 functions by
binding a (A/T)GATA(A/G) motif within regulatory regions
of promoters and enhancers to activate transcription. The
GATA-1 protein contains two zinc ¢nger domains; the car-
boxyl terminal domain (designated herein the cGATA-1 DNA
binding domain) has been shown to be su⁄cient for DNA
binding [37]. The solution structure of the complex between
the cGATA-1 DNA binding domain and a 16 bp duplex
DNA (Fig. 1A) has recently been determined at high resolu-
tion [38].
In the present study, we have incorporated ganciclovir at
the G position of the GATA recognition site of cGATA-1 and
have compared the binding a⁄nities of the complex of the
cGATA-1 DNA binding domain with the modi¢ed DNA
and the complex with the unmodi¢ed (control) DNA. In ad-
dition, we have qualitatively probed the structural e¡ects of
ganciclovir incorporation on the DNA-protein complex with
heteronuclear NMR chemical shift analysis of protein back-
bone proton/nitrogen and homonuclear chemical shift analysis
of DNA exchangeable proton resonances. We have also ex-
amined the e¡ects of including the antineoplastic drug araC in
the binding region of the DNA duplex.
2. Materials and methods
2.1. Preparation of the cGATA-1 DNA binding domain
The 15N labeled DNA binding domain of the chicken GATA-1
protein was expressed in Escherichia coli in minimal medium contain-
ing [15N]NH4Cl as the sole nitrogen source. The crude protein was
puri¢ed on DEAE-Sepharose Fast Flow (Pharmacia) followed by S-
Sepharose Fast Flow (Pharmacia). The protein was then puri¢ed by
reverse phase HPLC in TFA/acetonitrile. HPLC fractions were pooled
and lyophilized to dryness. The lyophilized protein was then sus-
pended as 0.15 mM solution with 1.1 eq. of zinc in 0.05% TFA.
The pH of the sample was slowly raised to 6.5 with dilute NaOH.
A complete description of the expression and puri¢cation of the cGA-
TA-1 DNA binding domain can be obtained from Omichinski et al.
[37,38].
2.2. Oligonucleotide synthesis and DNA duplex preparation
The araC phosphoramidite was supplied by Glen Research (Ster-
ling, VA). The enantiomerically pure ganciclovir phosphoramidite was
synthesized as described in Marshalko et al. [39]. All oligonucleotides
were synthesized by Oligos etc. (Wilsonville, OR). The DNA control
duplex strands 5P-GTTGCAGATAAACATT-3P and 5P-AATGTT-
TATCTGCAAC-3P were synthesized on a 10 Wmol scale and puri¢ed
by reverse phase HPLC before and after detritylation. The modi¢ed
araC strand 5P- AATGTTTATXTGCAAC-3P (X = araC) was synthe-
sized on a 0.2 Wmol scale, detritylated, and gel puri¢ed. The ganciclo-
vir-containing oligonucleotide strand 5P-GTTGCAZATAAACATT-3P
(Z = ganciclovir) was synthesized in two 1.0 Wmol scale syntheses, and
puri¢ed by reverse phase HPLC before and after detritylation. The
annealing of both the control and ganciclovir duplexes were moni-
tored by 1H NMR. Single strands were titrated with their complemen-
tary strand until NMR signals from each strand became equally in-
tense at 65‡C, then cooled slowly to room temperature. The araC
duplex was annealed by combining equal quantities of each strand
in H2O. The solution was then heated to 90‡C and cooled slowly to
room temp. The annealed product was checked by gel electrophoresis.
2.3. Preparation of radiolabeled probes
Double stranded oligonucleotides were end-labeled with 32P in a
reaction mixture containing 100 mM Tris-HCl (pH 7.5), 10 mM
MgCl2, 5 mM DTT, 10 units of T4 polynucleotide kinase (Strata-
gene), 10 WCi [Q-32P]ATP (Amersham), and 10 pmol of oligonucleotide
in a total volume of 20 Wl. Unincorporated [Q-32P]ATP was removed
from the reaction with Sephadex G-25 spin columns (Boehringer
Mannheim).
2.4. Gel mobility shift assays
Unless otherwise speci¢ed, gel mobility shift assays were performed
with 6 pmol of peptide in a total volume of 20 Wl containing 25 mM
HEPES pH 7.9, 50 mM KCl, 6.25 mM MgCl2, 0.5 mM DTT, 0.1 mM
EDTA, 0.1% NP40, and 5% glycerol. DNA was added to the reaction
mixture prior to a 15 min incubation on ice. After incubation samples
were loaded onto a 5% non-denaturing polyacrylamide gel (29:1
acrylamide:bis-acrylamide, running bu¡er: 0.5UTBE, pH 8.3). To
ensure the binding reactions entered the gel as quickly as possible,
samples were loaded onto a running gel. Electrophoresis was carried
out 4‡C for 45 min at 15 V/cm. Gels were dried under vacuum at 80‡C
for 1 h, and radioactivity in DNA bands was quanti¢ed with a Beta-
scope (Betagen). All binding experiments were carried out in tripli-
cate.
2.5. NMR spectroscopy
The ganciclovir-modi¢ed DNA-protein complex was prepared by
titrating a DNA solution (1.3 ml, V200 WM DNA, 10 mM NaCl)
with the cGATA-1 DNA binding domain (V0.14 mM, 0.05% TFA,
pH 6.5) until a 1:1 ratio was obtained (a precipitate formed if the
peptide was added in excess). The solution was then concentrated with
a Centricon-3 ultra¢ltration device (Amicon). The ¢nal solution was
adjusted to a volume of 250 Wl, and was placed in a Shigemi 5 mm
microtube. The ¢nal sample contained 1.0 mM complex and 10 mM
NaCl in 10% D2O/90% H2O. The unmodi¢ed DNA-protein complex
was prepared in the same manner.
All NMR experiments were performed on a Varian 600 MHz Unity
Plus spectrometer at a regulated temperature of 20‡C. Pulsed ¢eld
gradient sensitivity-enhanced 1H-15N HSQC [40] spectra were col-
lected for both the control and ganciclovir-containing DNA-protein
complexes. The water resonance was suppressed with a water £ipback
selective pulse. The data were acquired in the phase-sensitive mode of
States-TPPI with 2048 complex points in t2 (1H) and 256 complex
points in t1 (15N). The 1H and 15N spectral widths were 7500 Hz
and 2000 Hz, respectively. GARP 15N decoupling was utilized during
the acquisition period. 200 ms NOESY spectra for the control and
ganciclovir-DNA complex were acquired with an excitation sculpting
pulse for solvent suppression [41]. Selective 180‡ pulses were applied
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Fig. 1. Sequence composition of DNA duplexes containing the
GATA binding site. A: Unmodi¢ed duplex. B: Ganciclovir-substi-
tuted duplex. C: AraC-substituted duplex.
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Fig. 2. 1H-15N HSQC 2D contour plots of the control unmodi¢ed DNA-protein complex (A) and the ganciclovir DNA-protein complex (B).
Assignments were made as described in Section 3.
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with a SEDUCE pro¢le to suppress the water resonance. Gradient
pulses were applied along the z axis for 1 ms at 15 and 3 G/cm with 50
Ws delays before and after the gradient pulses. These experiments were
collected with States-TPPI phase cycling with 2048 complex points in
t2 and 1024 complex points in t1, a relaxation delay of 2.5 s, and a
spectral width of 12 500 Hz.
NMR data were processed with NMRpipe software [42]. The
HSQC and NOESY experiments were processed with a cosine bell
squared window function in the direct dimension and a squared-sine
bell shifted 60‡ in the indirect dimension. Data in the indirect dimen-
sion for both sets of experiments was zero-¢lled to 2048 points. After
zero ¢lling, the NOESY spectra had a digital resolution of 6 Hz/pt
and the HSQC 3.4 Hz/pt in proton and 1 Hz/pt in nitrogen.
3. Results
3.1. DNA binding
The consequences on DNA binding a⁄nity of nucleoside
analog incorporation into the DNA binding sequence of
GATA-1 were assessed with a gel mobility shift assay. Three
shift assays were performed in this study: (1) a control un-
modi¢ed DNA-cGATA-1 protein assay, (2) a ganciclovir-
modi¢ed DNA-cGATA-1 protein assay, and (3) an araC-
modi¢ed DNA-cGATA-1 protein assay. Radioactivity in
bands representing bound and free DNA were quanti¢ed
and analyzed by Scatchard analysis to provide dissociation
constants (Kd) for the DNA-protein interactions. The dissoci-
ation constant for the unmodi¢ed control DNA-cGATA-1
protein complex was determined to be 10 þ 5 nM, which is
equivalent to the value that was previously observed for this
sequence [37]. Scatchard analysis for the ganciclovir-modi¢ed
DNA-cGATA-1 protein complex gave a dissociation constant
of 100 þ 20 nM, 10-fold larger than the control. In contrast to
the e¡ect on DNA binding produced by the ganciclovir mod-
i¢cation, the introduction of araC into the DNA duplex did
not signi¢cantly a¡ect the dissociation constant (Kd = 10 þ 1
nM).
3.2. Chemical shift analysis
The reduction in binding a⁄nity produced by the ganciclo-
vir modi¢cation prompted us to examine the protein for struc-
tural changes using the 1H-15N HSQC experiment. The results
of 1H-15N HSQC experiments on both the control and ganci-
clovir-modi¢ed DNA-cGATA-1 protein complex are shown
in Fig. 2. The chemical shifts of the backbone 1H-15N reso-
nances in the control DNA-cGATA-1 protein complex experi-
ment were essentially identical to those that were previously
reported [38] ; consequently, assignments of the peaks were
made from this earlier work. Assignments of the peaks in
the HSQC spectrum of the ganciclovir-modi¢ed DNA-cGA-
TA-1 protein complex were made by comparison with the
control complex spectrum since only relatively small changes
were observed (proton 6 60 Hz, nitrogen 6 40 Hz). The con-
trol DNA-cGATA-1 protein complex and the ganciclovir-
modi¢ed DNA-cGATA-1 protein complex resonances were
nearly superimposable except for several changes that were
observed at key protein-DNA contact points. The absolute
value of the backbone 1H-15N chemical shift di¡erence be-
tween the control and ganciclovir-modi¢ed DNA-cGATA-1
protein complexes are plotted in Fig. 3. Although the chem-
ical shift changes are dispersed throughout the protein se-
quence, the signi¢cant changes (s 2US.D.) are concentrated
in two distinct regions of the protein. The ¢rst of these two
regions includes residues 15^19, which make up L-strand 3
and the loop connecting it to L-strand 2. The second region
includes residues 28^38, which make up the K-helix that lies
in the major groove of the DNA. Both of these regions
are involved in base contacts in the major groove of the
DNA.
Seven residues in the ganciclovir-modi¢ed DNA-cGATA-1
protein complex exhibit combined 1H-15N chemical shift
changes greater than twice the standard deviation of the
mean di¡erence. These residues include threonine-16, leu-
cine-17, arginine-19, arginine-20, leucine-33, lysine-36, and
glutamine-39. The combined backbone 1H-15N chemical shift
di¡erences for these residues are 48, 47, 32, 48, 42, 66, and 39
Hz, respectively. With the exception of glutamine-39 all the
residues either interact directly with the DNA or are part of
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Fig. 3. Sum of the absolute value of vN1H and vN15N chemical shift di¡erences for backone resonances of the ganciclovir DNA-protein com-
plex and control unmodi¢ed DNA-protein complex. 1H chemical shift di¡erences are in black and 15N chemical shift di¡erences are in white.
Protein secondary structure is indicated for selected regions. The horizontal segmented line represents twice the standard deviation of the mean
chemical shift di¡erence.
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secondary structure that interacts with the DNA in the con-
trol unmodi¢ed DNA-cGATA-1 protein complex [38].
In order to provide information on the structural integrity
of the DNA, a chemical shift comparison was performed for
the exchangeable and H2 DNA protons in the control and
ganciclovir-modi¢ed DNA-protein complex. Assignment of
the guanosine H1, cytosine NHP/HQ, thymine H3, and adenine
H2 protons in both complexes were made from 2-D NOESY
spectra utilizing an excitation sculpting technique to suppress
water [41]. Chemical shift changes in the imino and amino
protons of the DNA in both complexes are consistent with
one another with the exception of three residues, including the
ganciclovir (G7) site. In the ganciclovir-modi¢ed DNA-pro-
tein complex, up¢eld shifts of 150 Hz and 120 Hz are ob-
served for the imino protons of T25 and T27, respectively.
The imino proton of ganciclovir (G7 residue site) exhibits a
down¢eld shift of 60 Hz.
4. Discussion
Both araC and ganciclovir have been studied extensively
from the standpoint of the biochemical consequences of these
analogs on DNA polymerase function. Much is also known
about the structural e¡ects of these analogs when incorpo-
rated into DNA duplexes. While it is important to fully
understand the e¡ects of the analogs in free duplex DNA, it
cannot be assumed that these same structural consequences
predominate in a DNA-protein complex. The biophysical ex-
periments presented herein represent the ¢rst results obtained
with these analogs and a protein that is not a DNA polymer-
ase.
When araC, an analog of cytosine, is incorporated into
DNA, few signi¢cant structural distortions are observed in a
free DNA duplex in solution [29]. In the solution structure of
the control DNA-cGATA-1 protein complex, the side chains
of arginine-56 and serine-59 have hydrophobic interactions
with the furanose ring of C26 in the minor groove of the
DNA [38]. The 2P-hydroxyl group of araC, however, pro-
trudes into the major groove of the DNA [29] in a location
where no interactions occur with the protein. Given the above
information, the lack of a signi¢cant change in binding a⁄nity
in the cGATA-1 DNA binding domain complex when araC is
incorporated at position 26 of the DNA binding sequence was
not unexpected. Although the araC modi¢ed DNA-cGATA-1
protein complex was not included in the present NMR stud-
ies, it may be worthwhile in future studies to examine whether
the hydroxyl group on araC participates in hydrogen bonding
or alters the dynamics in the complex. The 2P hydroxyl group
of araC appears to be capable of forming intramolecular hy-
drogen bonds with backbone phosphate groups in self-com-
plementary duplexes [29] and in primer-template duplexes (un-
published results).
Ganciclovir, an analog of deoxyguanosine, lacks a 2P car-
bon atom resulting in an acyclic sugar. Using high resolution
NMR, we have demonstrated that when incorporated into a
DNA decamer duplex, ganciclovir signi¢cantly perturbs the
local structure of the double helix [20]. More speci¢cally, gan-
ciclovir induces a conformational change in the residue 3P to
the incorporation site and creates a kink in the backbone. The
base of ganciclovir exhibits some additional stacking interac-
tions in the helix but generally is not perturbed [20]. Despite
these signi¢cant changes in the structure of free DNA, it was
still not clear to us how ganciclovir incorporation would a¡ect
the structure of a DNA-protein complex.
When bound to DNA, the cGATA-1 DNA binding domain
protein folds into a structure containing four L-strands (resi-
dues 5^27), an K-helix (residues 28^38), and a long loop (res-
idues 39^51). The K-helix and the loop connecting strands L2
and L3 of the protein orient in the major groove of the DNA
while the carboxyl-terminal tail wraps around the DNA and
lies in the minor groove [38]. Many of these interactions in-
volve hydrophobic contacts with the furanose rings and bases
of various residues within the DNA duplex, including residue
G7, the site of ganciclovir incorporation. Consequently, it was
not very surprising to ¢nd that ganciclovir incorporation had
a negative impact on the DNA binding a⁄nity to this zinc
¢nger protein. Due to the greater degrees of freedom allowed
in DNA containing ganciclovir, the decrease in binding a⁄n-
ity could have been entirely due to entropic e¡ects. As de-
scribed in more detail below, the NMR data that we have
obtained implies that this change in binding a⁄nity has a
structural basis.
Seven residues in the ganciclovir-modi¢ed DNA-cGATA-1
protein complex exhibit backbone 1H-15N chemical shift
changes s 29 Hz (twice the standard deviation of the mean
di¡erence) compared to the unmodi¢ed DNA-cGATA-1 pro-
tein complex (Fig. 3). These residues include threonine-16,
leucine-17, arginine-19, arginine-20, leucine-33, lysine-36,
and glutamine-39. Threonine-16, leucine-17, and arginine-19
are part of L-strand 3 and the loop connecting it to L-strand 2
(Fig. 4) [38]. Threonine-16 makes hydrophobic contacts with
DNA residues A24 and T25 in the control DNA-protein com-
plex [38]. A combined 1H-15N shift of 48 Hz is observed for
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Fig. 4. Model illustrating the interaction of the DNA binding do-
main of cGATA-1 with unmodi¢ed DNA containing the GATA
binding site [37]. The DNA is depicted as a molecular surface with
site of ganciclovir incorporation in the ganciclovir DNA-protein
complex (residue G7) highlighted. The protein is represented as a
backbone ribbon encapsulating the zinc atom. The side chains of
protein residues exhibiting backbone 1H-15N chemical shift changes
in the ganciclovir DNA-protein complex are shown. The model was
generated with Insight95.0 (Molecular Simulations, Inc.).
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this amino acid in the ganciclovir-modi¢ed DNA-cGATA-1
protein complex. The side chain of leucine-17, which exhibits
a combined amide 1H-15N shift of 47 Hz, forms hydrophobic
interactions with the bases of A6, G7 (ganciclovir site), and
T25 (complementary to A8) in the major groove of the DNA.
The side chain of arginine-19 forms salt bridges and/or hydro-
gen bonds with the 5P phosphate of the G7 residue in the
control DNA-cGATA-1 protein complex. The 32 Hz up¢eld
change in chemical shift of the amide nitrogen in arginine-19
in the ganciclovir-modi¢ed DNA-cGATA-1 protein complex
could be due to a conformational change in the residue in
response to an altered backbone shape in DNA containing
ganciclovir.
The combined amide 1H-15N shifts of leucine-33 and lysine-
36 were 42 Hz and 66 Hz, respectively. Both residues are part
of the K-helix that lies in the major groove of the DNA and
interacts primarily through hydrophobic contacts with the
bases and sugars in the GATA recognition sequence (G7 to
T9; T22 to T26). In the case of leucine-33, the side chain
makes contacts with the sugars of T23 and A24 in the strand
opposite the site of ganciclovir incorporation. The amide 1H-
15N of lysine-36 exhibits the largest change in chemical shift
but was not shown to contact the DNA in the solution struc-
ture of the control DNA-cGATA-1 protein complex [38],
although it lies very close (ca. 6 7 Aî ) to the base of DNA
residue T9.
Arginine-20 and glutamine-39 exhibit absolute amide 1H-
15N shifts of 48 Hz and 39 Hz, respectively. Neither residue
was previously reported to contact the DNA in the unmodi-
¢ed DNA-cGATA-1 protein complex. However, arginine-20
is part of L-strand 3 and the loop connecting it to L-strand
2, and glutamine-39 is the N-terminal residue connecting
to the K-helix which probes the DNA major groove (Fig. 4)
[38].
Chemical shift changes of the exchangeable and H2 DNA
protons are limited to the ganciclovir residue and the A-T
base pairs adjacent to the ganciclovir residue (Fig. 1B). The
60 Hz down¢eld shift of the ganciclovir imino proton was not
previously observed in free duplex DNA [20]. Whether the
changes in chemical shift observed in the DNA exchangeable
protons around the ganciclovir residue are the result of the
ganciclovir substitution on the structure of the bound DNA
or on interactions with the protein is therefore uncertain. In a
free decamer DNA duplex containing ganciclovir, an up¢eld
shift of 84 Hz is observed for the imino proton of the thymine
in the same relative location as T25 is in the 16-mer duplex in
this study (i.e. one residue 3P to ganciclovir in the complemen-
tary strand). Analysis of the solution structure of the decamer
suggested that this chemical shift was probably due to the
markedly increased opening and slide observed at this base
pair [20]. Although the chemical shift in the free duplex is not
as large as the 150 Hz shift seen for the T25 imino proton in
the protein-bound DNA, the changes may be of the same
origin. The side chain of leucine-17 forms hydrophobic inter-
actions with the base of T25 as previously discussed. The
chemical shift in the amide group of leucine-17 may also be
related to the increased shift observed at T25. The imino
proton of T27 in the ganciclovir-DNA complex shows an up-
¢eld shift of 120 Hz. An A-T base pair was not located 5P to
ganciclovir residue in the free decamer duplex previously
studied [20], so no direct comparison between that duplex
and residue T27 in the DNA-protein complex can be made.
The results that we have presented suggest a change in the
binding interaction between the cGATA-1 DNA binding do-
main and DNA containing ganciclovir. Amide proton and
nitrogen chemical shift analysis suggests that the changes in
the interaction are localized to the K-helix, L-strand 3 and the
loop connecting it to L-strand 2 of the protein. The amino
acid residues in these regions probe the major groove in the
control DNA-protein complex at the site of ganciclovir incor-
poration (G7) and 3P to it [38]. 1H-15N chemical shift changes
observed in residues 17 and 19 suggest the presence of a local
distortion in protein structure in response to the ganciclovir
substitution in the GATA site. These residues interact with
the ganciclovir residue directly and it would not be unreason-
able to postulate some conformational changes in these pro-
tein residues. However, other chemical shift data suggests a
larger or more global e¡ect such as a change in the binding
mode of the complex when ganciclovir is incorporated into
the GATA site. The decrease in binding a⁄nity observed for
the ganciclovir DNA-protein complex may be the result of an
altered or secondary mode of binding whereby the normal
secondary structure of the protein is altered to accommodate
a distorted DNA structure.
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